Related references
Note: Only part of the references are listed.Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos
Golara Golbaghi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Potentiating apoptosis and modulation of p53, Bcl2, and Bax by a novel chrysin ruthenium complex for effective chemotherapeutic efficacy against breast cancer
Souvik Roy et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Unprecedented inhibition of P-gp activity by a novel ruthenium-cyclopentadienyl compound bearing a bipyridine-biotin ligand
Leonor Corte-Real et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Breast Cancer Treatment
Adrienne G. Waks et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Organoruthenium(II) Complexes Bearing an Aromatase Inhibitor: Synthesis, Characterization, in Vitro Biological Activity and in Vivo Toxicity in Zebrafish Embryos
Golara Golbaghi et al.
ORGANOMETALLICS (2019)
NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry
Enzo Alessio et al.
MOLECULES (2019)
Ruthenium-Cyclopentadienyl Bipyridine-Biotin Based Compounds: Synthesis and Biological Effect
Leonor Corte-Real et al.
INORGANIC CHEMISTRY (2019)
Exploring cellular uptake, accumulation and mechanism of action of a cationic Ru-based nanosystem in human preclinical models of breast cancer
Marialuisa Piccolo et al.
SCIENTIFIC REPORTS (2019)
Non-platinum complexes containing releasable biologically active ligands
Pavel Starha et al.
COORDINATION CHEMISTRY REVIEWS (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433
Susan Monro et al.
CHEMICAL REVIEWS (2019)
Development of Natural Product-Conjugated Metal Complexes as Cancer Therapies
Dik-Lung Ma et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Transport of the Ruthenium Complex [Ru(GA)(dppe)2]PF6 into Triple-Negative Breast Cancer Cells Is Facilitated by Transferrin Receptors
Marina A. Naves et al.
MOLECULAR PHARMACEUTICS (2019)
Enhancement of therapeutic effect in breast cancer with a steroid-conjugated ruthenium complex
Gaochao Lv et al.
NEW JOURNAL OF CHEMISTRY (2019)
Nucleus-enriched Ruthenium Polypyridine Complex Acts as a Potent Inhibitor to Suppress Triple-negative Breast Cancer Metastasis In vivo
Xuanhao Zhao et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2019)
Cisplatin nephrotoxicity: a review of the literature
Sandhya Manohar et al.
JOURNAL OF NEPHROLOGY (2018)
An estrogen receptor targeted ruthenium complex as a two-photon photodynamic therapy agent for breast cancer cells
Xueze Zhao et al.
CHEMICAL COMMUNICATIONS (2018)
Ruthenium(II) arene NSAID complexes: inhibition of cyclooxygenase and antiproliferative activity against cancer cell lines
Poulami Mandal et al.
DALTON TRANSACTIONS (2018)
The side effects of platinum-based chemotherapy drugs: a review for chemists
Rabbab Oun et al.
DALTON TRANSACTIONS (2018)
The trans-[Ru(PPh3)2(N,N-dimethyl-N′-thiophenylthioureato-k2O,S)(bipy)] PF6 complex has pro-apoptotic effects on triple negative breast cancer cells and presents low toxicity in vivo
Amanda Blanque Becceneri et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2018)
Phosphine/diimine ruthenium complexes with Cl-, CO, NO+, NO2-, NO3- and pyridine ligands: Pro-apoptotic activity on triple-negative breast cancer cells and DNA/HSA interactions
Henrique Vieira Reis Silva et al.
POLYHEDRON (2018)
Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases
Nerino Allocati et al.
ONCOGENESIS (2018)
Metastatic and triple-negative breast cancer: challenges and treatment options
Sumayah Al-Mahmood et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells
Jitka Pracharova et al.
DALTON TRANSACTIONS (2018)
Deciphering Steroid Receptor Crosstalk in Hormone-Driven Cancers
Thu H. Truong et al.
ENDOCRINOLOGY (2018)
Anti-Proliferative and Anti-Migration Activity of Arene-Ruthenium(II) Complexes with Azole Therapeutic Agents
Legna Colina-Vegas et al.
INORGANICS (2018)
In Vivo Performance of a Ruthenium-cyclopentadienyl Compound in an Orthotopic Triple Negative Breast Cancer Model
Nuno Mendes et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2017)
Thirty Years of the Drug Candidate NAMI-A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective
Enzo Alessio
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY (2017)
The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis
Akshay Jain et al.
JOURNAL OF CONTROLLED RELEASE (2017)
A Molecular Combination of Zinc(II) Phthalocyanine and Tamoxifen Derivative for Dual Targeting Photodynamic Therapy and Hormone Therapy
Feng-Ling Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer
Jianliang Shen et al.
NANO LETTERS (2017)
Diruthenium(II,III) metallodrugs of ibuprofen and naproxen encapsulated in intravenously injectable polymer-lipid nanoparticles exhibit enhanced activity against breast and prostate cancer cells
Samara R. Alves Rico et al.
NANOSCALE (2017)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Potential role of CYP1B1 in the development and treatment of metabolic diseases
Fei Li et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Ruthenium(II)/triphenylphosphine complexes: An effective way to improve the cytotoxicity Of lapachol
Katia M. Oliveira et al.
POLYHEDRON (2017)
Synthesis, characterization and biological evaluation of ruthenium flavanol complexes against breast cancer
Ashok Kumar Singh et al.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY (2017)
Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action
Carlo Irace et al.
SCIENTIFIC REPORTS (2017)
Cortisol overproduction results from DNA methylation of CYP11B1 in hypercortisolemia
Mitsuhiro Kometani et al.
SCIENTIFIC REPORTS (2017)
Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells
Cecilia P. Popolin et al.
PLOS ONE (2017)
Tumoral expression of drug and xenobiotic metabolizing enzymes in breast cancer patients of different ethnicities with implications to personalized medicine
Yan Li et al.
SCIENTIFIC REPORTS (2017)
Gallic acid induces G1 phase arrest and apoptosis of triple-negative breast cancer cell MDA-MB-231 via p38 mitogen-activated protein kinase/p21/p27 axis
Hsiang-Lin Lee et al.
ANTI-CANCER DRUGS (2017)
Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage
Ana Zamora et al.
DALTON TRANSACTIONS (2017)
Renewed interest in the progesterone receptor in breast cancer
Elgene Lim et al.
BRITISH JOURNAL OF CANCER (2016)
EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape
Seung-Oe Lim et al.
CANCER RESEARCH (2016)
BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds
Khwanjira Hongthong et al.
CURRENT CANCER DRUG TARGETS (2016)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
The water soluble ruthenium(II) organometallic compound [Ru(p-cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells
Maura Montani et al.
PHARMACOLOGICAL RESEARCH (2016)
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants
Fresia Pareja et al.
NPJ BREAST CANCER (2016)
Ruthenium(II) Complexes Containing Anti-Inflammatory Drugs as Ligands: Synthesis, Characterization and in vitro Cytotoxicity Activities on Cancer Cell Lines
Junai C. S. Lopes et al.
JOURNAL OF THE BRAZILIAN CHEMICAL SOCIETY (2015)
Discovery of a dual-targeting organometallic ruthenium complex with high activity inducing early stage apoptosis of cancer cells
Jun Du et al.
METALLOMICS (2015)
Zebrafish as tools for drug discovery
Calum A. MacRae et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Combination of Ru(II) complexes and light: new frontiers in cancer therapy
Cristina Mari et al.
CHEMICAL SCIENCE (2015)
Ruthenium Polypyridyl Complex Inhibits Growth and Metastasis of Breast Cancer Cells by Suppressing FAK signaling with Enhancement of TRAIL-induced Apoptosis
Wenqiang Cao et al.
SCIENTIFIC REPORTS (2015)
Optimal management of hormone receptor positive metastatic breast cancer in 2016
Tomas Reinert et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)
Growth inhibitory activity for cancer cell lines of lapachol and its natural and semi-synthetic derivatives
Serena Fiorito et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine
Tidarat Nhukeaw et al.
BMC CANCER (2014)
Metal-based anticancer chemotherapeutic agents
Nafees Muhammad et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2014)
Cisplatin in cancer therapy: Molecular mechanisms of action
Shaloam Dasari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity
Zhigang Wang et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2014)
In Vitro and in Vivo Evaluation of Water-Soluble Iminophosphorane Ruthenium(II) Compounds. A Potential Chemotherapeutic Agent for Triple Negative Breast Cancer
Malgorzata Frik et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Lapachol and its congeners as anticancer agents: a review
Francesco Epifano et al.
PHYTOCHEMISTRY REVIEWS (2014)
In vivo anti-tumor activity of the organometallic ruthenium(II)-arene complex [Ru(η6-p-cymene)-Cl2(pta)] (RAPTA-C) in human ovarian and colorectal carcinomas
Andrea Weiss et al.
CHEMICAL SCIENCE (2014)
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
Robert Trondl et al.
CHEMICAL SCIENCE (2014)
Luminescent iminophosphorane gold, palladium and platinum complexes as potential anticancer agents
Malgorzata Frik et al.
INORGANIC CHEMISTRY FRONTIERS (2014)
Gallic acid: Molecular rival of cancer
Sharad Verma et al.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY (2013)
Enzyme inhibition by metal complexes: concepts, strategies and applications
Kelly J. Kilpin et al.
CHEMICAL SCIENCE (2013)
Interaction of apo-transferrin with anticancer ruthenium complexes NAMI-A and its reduced form
Olga Mazuryk et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2012)
Synthesis of organometallic ruthenium(II) complexes with strong activity against several human cancer cell lines
Tania S. Morais et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2012)
New Ruthenium(II)-Letrozole Complexes as Anticancer Therapeutics
Annie Castonguay et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Insight into the binding interactions of CYP450 aromatase inhibitors with their target enzyme: a combined molecular docking and molecular dynamics study
Roberta Galeazzi et al.
JOURNAL OF MOLECULAR MODELING (2012)
Organometallic Palladium Complexes with a Water-Soluble Iminophosphorane Ligand As Potential Anticancer Agents
Monica Carreira et al.
ORGANOMETALLICS (2012)
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
Tomasz Byrski et al.
BREAST CANCER RESEARCH (2012)
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
Alberta Bergamo et al.
DALTON TRANSACTIONS (2011)
A Potent Ruthenium(II) Antitumor Complex Bearing a Lipophilic Levonorgestrel Group
Jose Ruiz et al.
INORGANIC CHEMISTRY (2011)
Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells
Jing Xie et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2011)
A bifunctional organometallic ruthenium drug with multiple modes of inducing apoptosis
Soumya Chatterjee et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2011)
(Arene)Cl2Ru(II) complexes with N-coordinated estrogen and androgen isonicotinates: Interaction with sex hormone binding globulin and anticancer activity
Rainer Schobert et al.
STEROIDS (2011)
Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects
Ana-Maria Florea et al.
Cancers (2011)
Mechanism-Based Tumor-Targeting Drug Delivery System. Validation of Efficient Vitamin Receptor-Mediated Endocytosis and Drug Release
Shuyi Chen et al.
BIOCONJUGATE CHEMISTRY (2010)
Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients
Nebu Koshy et al.
BREAST (2010)
Poly(ADP-Ribose) Polymerase Inhibition: Targeted Therapy for Triple-Negative Breast Cancer
Carey K. Anders et al.
CLINICAL CANCER RESEARCH (2010)
Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin
Igor P. Pogribny et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells
Jimmy M. -M. Kwok et al.
MOLECULAR CANCER RESEARCH (2010)
Mitochondrial Uncoupling and the Warburg Effect: Molecular Basis for the Reprogramming of Cancer Cell Metabolism
Ismael Samudio et al.
CANCER RESEARCH (2009)
Synthesis of Apoptosis-Inducing Iminophosphorane Organogold(III) Complexes and Study of Their Interactions with Biomolecular Targets
Neha Shaik et al.
INORGANIC CHEMISTRY (2009)
New derivatives of vitamin B12 show preferential targeting of tumors
Robert Waibel et al.
CANCER RESEARCH (2008)
Chemopreventive effects of natural dietary compounds on cancer development
Min-Hsiung Pan et al.
CHEMICAL SOCIETY REVIEWS (2008)
New trends for metal complexes with anticancer activity
Pieter C. A. Bruijnincx et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2008)
Targeted therapy for cancer using PARP inhibitors
Christopher J. Lord et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug development
Robert D. Bruno et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Synthesis of azole nucleoside analogues of D-pinitol as potential antitumor agents
Tianrong Zhan et al.
CARBOHYDRATE RESEARCH (2007)
Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms
Carsten A. Vock et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Multi-target therapeutics: when the whole is greater than the sum of the parts
Grant R. Zimmermann et al.
DRUG DISCOVERY TODAY (2007)
An estrogen-platinum terpyridine conjugate: DNA and protein binding and cellular delivery
Michael J. Hannon et al.
CHEMISTRY-A EUROPEAN JOURNAL (2006)
Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy
Wee Han Ang et al.
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY (2006)
Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective
Jennifer R. Garreau et al.
AMERICAN JOURNAL OF SURGERY (2006)
Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women
Henning T. Mouridsen
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Metal complex SERMs (selective oestrogen receptor modulators).: The influence of different metal units on breast cancer cell antiproliferative effects
A Vessières et al.
DALTON TRANSACTIONS (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Breast cancer metastasis: Markers and models
B Weigelt et al.
NATURE REVIEWS CANCER (2005)
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes
C Scolaro et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Aromatase inhibitors in the treatment of breast cancer
RW Brueggemeier et al.
ENDOCRINE REVIEWS (2005)
Selective estrogen receptor modulators in the ruthenocene series.: Synthesis and biological behavior
P Pigeon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
57 varieties: the human cytochromes P450
DFV Lewis
PHARMACOGENOMICS (2004)
The role of COX-2 inhibition in breast cancer treatment and prevention
B Arun et al.
SEMINARS IN ONCOLOGY (2004)
Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (′Iressa′) is independent of EGFR expression level
M Campiglio et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2004)
The role of BRCA1 in the cellular response to chemotherapy
RD Kennedy et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Why do cancers have high aerobic glycolysis?
RA Gatenby et al.
NATURE REVIEWS CANCER (2004)
Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours
G Russell-Jones et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2004)
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy
WL Shao et al.
BREAST CANCER RESEARCH (2004)
Sex hormone-binding globulin is synthesized in target cells
SM Kahn et al.
JOURNAL OF ENDOCRINOLOGY (2002)
Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues
MJ Thun et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Estrogen-derived steroidal metal complexes: Agents for cellular delivery of metal centers to estrogen receptor-positive cells
A Jackson et al.
INORGANIC CHEMISTRY (2001)
Cyclooxygenase-5: a target for the prevention and treatment of breast cancer
LR Howe et al.
ENDOCRINE-RELATED CANCER (2001)
Catalytic differences between porcine blastocyst and placental aromatase isozymes
YC Kao et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2000)
Primary care:: Chemoprevention of colorectal cancer
PA Jänne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy
E Raymond et al.
DRUGS (2000)
Share Paper
